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Racial Disparities in Mortality Associated with Systemic Lupus 
Erythematosus — Fulton and DeKalb Counties, Georgia, 2002–2016
S. Sam Lim, MD1; Charles G. Helmick, MD2; Gaobin Bao, MPH1; Jennifer Hootman, PhD2;  
Rana Bayakly, MPH3; Caroline Gordon, MD4; Cristina Drenkard, MD, PhD1
Systemic lupus erythematosus (SLE) is a chronic, systemic 
autoimmune disease with often nonspecific symptoms that 
can lead to a delay in diagnosis. The disease disproportion-
ately affects women and minorities. Blacks with SLE also 
have more severe disease and develop it at an earlier age (1). 
Despite an increase in the 5-year survival rate from 50% in 
1955 to approximately 90% in the 2000s, attributed largely 
to advances in management of SLE (2), premature mortality 
among SLE patients persists, often as a result of disease severity, 
infections, and cardiovascular disease. Because existing SLE 
mortality estimates based on death certificate data are known 
to underestimate SLE deaths (3), SLE mortality was analyzed 
using 2002–2004 data from the population-based Georgia 
Lupus Registry (1). Incident and prevalent SLE cases matched 
to the National Death Index through 2016 identified 97 and 
401 deaths, respectively. Standardized mortality ratios adjusted 
for age group, sex, and race were two to three times higher 
among persons with SLE relative to expected deaths in the 
general population. Blacks had significantly higher cumulative 
mortality than did whites, and blacks with both incident and 
prevalent cases were significantly younger at death (mean age 
51.8 and 52.3 years, respectively) than were whites (mean age 
64.4 and 65.0 years, respectively). Whites had lower mortality 
after diagnosis than did blacks; among incident cases, mortality 
among whites did not occur until 5 years after SLE diagnosis, 
whereas blacks had significantly and persistently higher mor-
tality from the time of diagnosis. There were no significant 
differences by sex. Current CDC-supported efforts encourage 
early detection, diagnosis, and treatment, and enhanced self-
management skills to mitigate racial disparities and improve 
outcomes overall among persons with SLE.
The Georgia Lupus Registry (1) was designed to collect data on 
all residents of two Georgia counties (Fulton and DeKalb) in the 
Atlanta metropolitan area with large black and white populations. 
The public health surveillance exemption to the Health Insurance 
Portability and Accountability Act Privacy Rule (https://www.hhs.
gov/hipaa/for-professionals/privacy/index.html) allowed investiga-
tors to obtain protected health information (PHI) without written 
consent of the patient. Application of this exemption enabled 
investigators to ascertain all potential cases, determine whether 
potential cases met case definition criteria, and provide enough 
information to prevent duplicate counting of patients examined 
in multiple facilities. PHI was stored securely, and its use was 
limited to authorized research personnel, maximizing the use of 
deidentified data whenever feasible.
The primary sources of potential cases included hospitals, 
rheumatologists, nephrology groups, and dermatology groups 
in and around the two counties. Administrative databases were 
queried retrospectively for billing codes for lupus and related 
conditions. Secondary sources included laboratories (includ-
ing pathology laboratories) and queries in other population 
databases (1). Abstractors were trained and underwent regular 
quality assessments. The study was reviewed and approved by 
the Institutional Review Boards at Emory University and the 
Georgia Department of Public Health. CDC determined this 
study did not meet the definition of human subjects research 
(public health practice). SLE prevalence was estimated for 
2002 and incidence for 2002–2004 from the Georgia Lupus 
Registry. Denominator data for the two counties were obtained 
from postcensal population estimates. Age-adjusted estimates 
and 95% confidence intervals were calculated based on the 
standard 2000 projected age distribution (1).
A case of SLE was defined as meeting either the 1997 update 
of the 1982 American College of Rheumatology (ACR) revised 
classification criteria (meeting four or more of the 11 criteria*) 
(4,5) or an alternative definition (three of the ACR criteria plus 
a documented diagnosis of SLE by the patient’s board-certified 
rheumatologist). All incident and prevalent SLE cases were 
matched to the National Death Index through 2016. Cause 
of death codes were available but not analyzed because of poor 
reliability regarding SLE attribution (3). Standardized mortal-
ity ratios were calculated as the ratio of observed deaths among 
persons with prevalent SLE to expected deaths in the general 
county populations; subgroups were compared using the same 
age group, sex, and race categories. The number of expected 
deaths was calculated by multiplying the death rate of the general 
population in Fulton and DeKalb counties by the total number 
of SLE patients in each group. There were too few deaths to cal-
culate standardized mortality ratios for the incident SLE group. 
Cumulative mortality used Kaplan-Meier survival analysis for 
both incident and prevalent cases to determine the percentage 
* The 11 criteria are as follows: malar rash, discoid rash, photosensitivity, oral 
ulcers, arthritis, serositis (pericarditis or pleuritis), renal disorder, neurologic 
disorder, hematologic disorder, immunologic disorder, and antinuclear antibody. 
https://www.rheumatology.org/Portals/0/Files/1997%20Update%20of%20
1982%20Revised.pdf.
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of SLE patients dying since their diagnosis (1). Analyses were 
performed using SAS software (version 9.4; SAS Institute).
During 2002–2004, a total of 336 incident SLE cases were 
identified; these SLE patients were demographically similar 
to the patients in 1,353 cases with prevalent SLE in 2002 
(87%–90% female, 74%–76% black, and 23% white) but were 
older at SLE diagnosis (mean age 40.6 years) than were patients 
with prevalent SLE (34.6 years). Among patients with prevalent 
and incident SLE, 401 and 97 deaths, respectively, occurred 
through 2016. Standardized mortality ratios using 2002–2016 
data were 2.3–3.3 times higher for persons with prevalent SLE 
relative to expected deaths in the general population (Table). 
Black females with prevalent SLE were three times more 
likely to die than were black females in the general population 
(standardized mortality ratio = 3.38). Cumulative mortality 
was significantly higher among blacks than among whites for 
both incident (Figure 1) and prevalent (Figure 2) SLE; death 
occurred at a younger age among blacks with incident SLE 
cases (mean age = 51.8 ± 17.5 years) and prevalent SLE cases 
(mean 52.3 ± 15.9 years) than it did among whites (64.4 ± 18.9 
years and 65.0 ± 16.3 years, respectively) (p<0.001). Mortality 
among whites was markedly lower in the years immediately 
following diagnosis compared with mortality among blacks; 
among incident cases, no deaths were observed among whites 
until 5 years after SLE diagnosis, whereas mortality among 
blacks was persistently higher from the time of diagnosis. In 
addition, whites with SLE had the same cumulative mortal-
ity proportion (9%) in 10 years as that observed in blacks in 
2 years (Figure 1). There were no significant differences by sex.
TABLE. Standardized mortality ratios for patients with prevalent cases 
of systemic lupus erythematosus (SLE) from 2002 to 2016, adjusted 
by age, sex, and black/white race* — Georgia Lupus Registry
Characteristic
No. of SLE 
patients (%)
Deaths Standardized 
mortality ratio  
(95% CI)Observed Expected
Overall (black  
and white†)
1,335 (100) 400 128 3.12 (2.83–3.44)
Sex
Male 135 (10.1) 51 17 2.98 (2.27–3.92)
Female 1,200 (89.9) 349 111 3.14 (2.83–3.49)
Race
Black 1,024 (76.7) 324 97 3.34 (3.00–3.72)
White 311 (23.3) 76 31 2.43 (1.94–3.04)
Race/Sex (total = 1,200)
Black female 924 (77.0) 287 85 3.38 (3.01–3.79)
White female 276 (23.0) 62 26 2.36 (1.84–3.02)
Abbreviation: CI = confidence interval.
* Age on July 1 was used for adjustment. The standardized mortality ratio is a 
ratio between the observed number of deaths in those with SLE and the 
number of deaths expected, based on age, sex, and race specific rates in Fulton 
and DeKalb counties. CIs are based on a generalized estimating equation 
model with Poisson distribution.
† Eighteen persons who were not identified as black or white, including one 
who died, were excluded.
FIGURE 1. Cumulative mortality* of incident systemic lupus 
erythematosus (SLE)  cases diagnosed during 2002–2004, by 
black/white race — Georgia Lupus Registry, 2002–2016
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* Cumulative mortality for incident SLE cases was calculated using Kaplan-Meier 
survival analysis to indicate the probability of SLE patients dying at a specified 
time since diagnosis. Difference p = 0.008, by log rank test.
Discussion
Despite increasing awareness of SLE and advancements in 
treatment (6), mortality among persons with SLE remains 
high, with the highest standardized mortality ratio among 
black females. The effect of this racial disparity in mortality is 
further underscored by the fact that the prevalence of SLE in 
blacks is three times that in whites (1).
These findings are similar to those reported in a 2002 study, 
which also found a higher incidence and prevalence among 
women and blacks, but the current study used more accurate 
methods to ascertain cases (7). A recent nationwide study 
using causes of death from 1968 through 2013 obtained from 
death certificate data in CDC’s WONDER database (https://
wonder.cdc.gov) showed that age-standardized mortality rates 
decreased over time among SLE patients but remained high 
relative to non-SLE mortality, with the highest mortality rates 
in women, blacks, and residents of the South and West U.S. 
Census regions (8). Both of these studies depended solely on 
death certificates to identify cases of SLE, which only capture 
an estimated 40%–60% of SLE cases (3,9).
The findings in this report are subject to at least four limitations. 
First, racial identity was assigned based primarily on the physician’s 
assessment as documented in the medical record, which might not 
reflect the patient’s self-identity. Second, some cases might have 
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FIGURE 2. Cumulative mortality* of prevalent systemic lupus 
erythematosus (SLE)  cases diagnosed in 2002, by black/white race — 
Georgia Lupus Registry, 2002–2016
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* Cumulative mortality for prevalent SLE cases was calculated using Kaplan-
Meier survival analysis to indicate the probability of SLE patients dying at a 
specified time since 2002. Difference p = 0.025, by log rank test.
been missed in the original registry. Third, there might be vari-
ability in SLE diagnosis by rheumatologists, and undiagnosed cases 
were not sought. Finally, these results might not be generalizable 
outside the two counties. Strengths of the current study include 
the use of a population-based lupus registry identifying nearly all 
validated SLE cases in the two-county area and the long follow-
up period, resulting in data on more SLE deaths than would be 
identified by death certificate diagnoses alone.
Prioritizing the identification of reversible mortality factors 
and developing strategies to address them could aid in mitigat-
ing racial disparities and improving outcomes overall in SLE. 
The first-ever National Public Health Agenda for Lupus (10) 
describes a plan to address lupus from a public health perspec-
tive. Other CDC-supported, population-based lupus registries 
and longitudinal follow-up activities include examining natural 
history, treatment, access to care, and disparities as potential 
factors in SLE mortality and progression (https://www.cdc.
gov/lupus/funded/lupus-studies.htm). The Lupus Foundation 
of America and the American College of Rheumatology are 
working together to encourage early detection and treatment 
of lupus, enhance the self-management skills of patients with 
lupus, and improve health care providers’ ability to make accu-
rate diagnoses. Additional information is available at https://
www.cdc.gov/lupus/funded/awareness.htm.
Summary
What is already known about this topic?
Systemic lupus erythematosus (SLE) is a systemic autoimmune 
disease that disproportionately affects women and minorities. 
The 5-year survival rate of patients with SLE has been improving.
What is added by this report?
Using improved methods by following SLE patients carefully 
defined in a population-based registry, standardized mortality 
ratios were two to three times higher in persons with SLE than 
in the general population. Compared with whites with SLE, 
cumulative SLE mortality was significantly higher among blacks, 
with deaths occurring sooner after diagnosis and at a mean age 
approximately 13 years younger.
What are the implications for public health practice?
Current CDC-supported efforts to encourage early detection, 
diagnosis, and treatment, and to enhance self-management 
skills might mitigate racial disparities and improve overall 
outcomes in SLE.
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